2016
Issues in Trial Design and Areas Needing Further Research
Abraldes J, Salerno F, Augustin S, Ripoll C, Reiberger T, Moreau R, Albillos A, Garcia-Tsao G. Issues in Trial Design and Areas Needing Further Research. 2016, 355-363. DOI: 10.1007/978-3-319-23018-4_35.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPrimary end pointVariceal bleedingEnd pointTrial designAppropriate primary end pointVariceal bleeding episodesComplications of cirrhosisNew therapeutic approachesBleeding episodesMultiple complicationsTherapeutic trialsCase mortalityTherapeutic approachesHigh riskLower riskPatientsClinical scenariosComplicationsBleedingPrevious trialsCirrhosisSecond complicationMortalityTrialsDeath
2002
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
Burroughs A, Groszmann R, Bosch J, Grace N, Garcia-Tsao G, Patch D, Garcia-Pagan J, Dagher L. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002, 50: 425. PMID: 11839726, PMCID: PMC1773121, DOI: 10.1136/gut.50.3.425.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientChronic hepatitis CVenous pressure gradientHepatitis CAntiviral therapyEnd pointChronic hepatitis C.Major healthcare problemBest end pointHepatitis C.HVPG measurementTherapeutic benefitTherapeutic evaluationTherapyHealthcare problemPatientsPressure gradientResponse